Helsinn expands high-potency plant with cytotoxics suite
March 8, 2011Manufacturing and Production APIs, CMOs, GMP, Helsinn, Helsinn Advanced Synthesis, Swiss pharma contract manufacturing, contract manufacturing, high-potency APIs
Helsinn is on track to complete construction of a new manufacturing plant for cytotoxic active pharmaceutical ingredients in Biasca, Switzerland, …
Pharma manufacturing news in brief
March 8, 2011Manufacturing and Production Bristol-Myers Squibb, CSM GlobalPharma, Carbogen Amcis, Quotient Clinical, SCM Pharma, WuXi PharmaTech
Facility updates from Bristol-Myers Squibb, WuXi PharmaTech, Quotient Clinical, CSM GlobalPharma and SCM Pharma, plus a reorganisation of Carbogen Amcis’ …
Ethical practices – pharma’s obligation
March 8, 2011Research and Development, Sales and Marketing ethics, industry relations, industry reputation
Pharmaceutical companies are not charities, and neither is any other business, by definition. Capitalism as a recognised system has been …
Service Insight: Emerging markets – a business development task or extreme fishing?
March 7, 2011Sales and Marketing Service Insight, Surelines Ltd, emerging markets
SERVICE INSIGHTEmerging markets, new business; call it what you will but invariably the responsibility for grasping this nettle falls to …
GSK ends neuroscience research alliance
March 7, 2011Research and Development GSK, GlaxoSmithKline, Targacept, neuronal nicotinic receptors, neuroscience research
GlaxoSmithKline has severed a strategic alliance formed in July 2007 with US biopharma company Targacept. GSK forked out $45 million …
GSK adds former Merck CFO to board
March 7, 2011Sales and Marketing GSK, GlaxoSmithKline, Judy Lewent, Stacey Cartwright, appointment, sales and marketing
GlaxoSmithKline has appointed Judy Lewent to its board as a non-executive director. She has previously served as an executive VP …
Government injects £775m into NHS translational research
March 7, 2011Research and Development ABPI, Kent, NHS research, Pfizer research Kent, Sandwich, Science and Technology Select Committee, translational research
The government has pledged around £775 million for translational research, saying it will help modernise the health service and support …
Eisai prepares ground for Halaven’s European launch
March 7, 2011Sales and Marketing Cancer, EMBRACE, Eisai, Halaven, advanced breast cancer, breast cancer, eribulin
Eisai has published further details of a phase III trial of its first-in-class chemotherapy drug Halaven ahead of its hoped-for …
Eisai to cut 900 jobs ahead of Aricept patent loss
March 7, 2011Sales and Marketing Aricept, Eisai, donepezil, generics, job cuts
Eisai is to cut around 900 jobs in Europe, the US and Japan over the next five years as it …
Novo’s Victoza beats Bydureon in head-to-head trial
March 4, 2011Research and Development, Sales and Marketing Alkermes, Amylin, Byureon, Victoza, diabetes, exenatide, lilly, type II diabetes
Bydureon has been outperformed by rival Victoza in a head-to-trial, decimating shares in its co-developer Amylin and Alkermes, the company …
Onglyza expands European licence
March 4, 2011Sales and Marketing AZ, AstraZeneca, BMS, Bristol-Myers Squibb, Onglyza, diabetes, renal impairment, saxagliptin, type II diabetes
European regulators have approved a licence extension for diabetes treatment Onglyza, making it the first drug in its class that …
First idiopathic pulmonary fibrosis drug approved
March 4, 2011Sales and Marketing Esbriet, IPF, InterMune, Orphan Drugs, idiopathic pulmonary fibrosis, orphan drug
The first ever treatment for the potentially fatal lung disease idiopathic pulmonary fibrosis (IPF) has been approved in the EU. …
Digital Pharma: online campaign directory updated
March 4, 2011Medical Communications, Sales and Marketing Digital Pharma blog, Novartis, Pfizer, Sanofi-Aventis, VTE, diabetes, erectile dysfunction, pharmacist educaiton, venous thromboembolism, viagra
The latest update to the Digital Pharma links directory covers its online campaigns section and includes a pharmacist networking portal …
Market forces won’t produce needed restructure, warns King’s Fund
March 4, 2011GP consortia, Health and Social Care Bill, Kings Fund, NHS, NHS Commissioning Board, NHS reforms, foundation trusts, hospital trusts, king's fund
Greater competition in the NHS is unlikely to bring about the restructuring needed in hospital services, according to The King’s …
Former McCann MD launches patient-focused agency
March 4, 2011Medical Communications Craig Mills, Frontera, healthcare communications agency, medical communications
An agency specialising in professional, consumer and public health has been launched by a former managing director at McCann Healthcare. …
Medical bodies back ABPI Code changes
March 4, 2011Medical Communications ABPI, ABPI Code of Practice, Code of Practice, GMC, INFORCE, Nottingham, Royal College of Physicians, industry relations, trust
Leading medical organisations have signed a joint declaration backing the forthcoming changes to UK pharma’s self-regulatory Code of Practice. In …
NICE rejects Lucentis for diabetic oedema
March 4, 2011Sales and Marketing Lucentis, NICE, Novartis, VEGF, Vascular Endothelial Growth Factor, diabetic oedema, raibizumab
NICE’s draft guidance has not recommended Lucentis for diabetic oedema after ‘faulty analysis’ from manufacturer Novartis was found not to …
Digital Pharma: European doctors’ communities collaborate
March 3, 2011Medical Communications, Sales and Marketing Coliquio, Digital Pharma blog, Doctors.net.uk, online doctors communities
Two of Europe’s leading medical professional communities have signed a strategic alliance that will see them collaborate on multi-market digital …
Jim McDermott to lead Quintiles Market Intelligence
March 3, 2011Sales and Marketing Jim McDermott, Quintiles, appointment, sales and marketing
Quintiles has appointed Jim McDermott as managing director of the Market Intelligence practice within its Consulting group. The practice provides …
Universities to ‘pick up pharma’s R&D mantle’ after Pfizer closure
March 3, 2011Research and Development Kent, Pfizer, Sandwich, Science and Technology Select Committee, UK research, UK science, job cuts
Science in the UK will have to focus on contractually-based research in the future as pharma’s R&D presence in the …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
